Clinical Trial: NCT02909777
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-02-11 |
Study Overview
Brief Summary
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
Official Title
Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Conditions
Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
Intervention / Treatment
- Drug: CUDC-907
Other Study ID Numbers
- 16-371
Start Date
2016-10
Primary Completion Date (Actual)
2025-12
Study Completion Date (Actual)
2025-12
Enrollment (Actual)
26
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-02-11 |
Study Overview
Brief Summary
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
Official Title
Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Conditions
Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
Intervention / Treatment
- Drug: CUDC-907
Other Study ID Numbers
- 16-371
Start Date
2016-10
Primary Completion Date (Actual)
2025-12
Study Completion Date (Actual)
2025-12
Enrollment (Actual)
26
Study Type
Interventional
Phase
Phase 1